Ionis Strengthens sHTG Leadership with New Data at ESC Congress 2026
Event summary
- Ionis to present one-year data on TRYNGOLZA (olezarsen) for severe hypertriglyceridemia (sHTG) at ESC Congress 2026.
- Phase 1 data on ION775, a next-gen siRNA with potential for semiannual dosing, to be unveiled.
- TRYNGOLZA approved in the U.S. for sHTG in June 2026; EU review ongoing with Sobi as commercial partner.
- Additional data on eplontersen for ATTR-CM to be presented in collaboration with AstraZeneca.
The big picture
Ionis is reinforcing its position in severe hypertriglyceridemia management with new long-term efficacy and safety data for TRYNGOLZA, while advancing its next-generation pipeline with ION775. The ESC Congress 2026 presentations come as Ionis seeks to expand TRYNGOLZA's global reach, with the EU review representing a key near-term catalyst. The company's focus on RNA-targeted therapies aligns with broader industry trends toward precision medicine in cardiovascular disease.
What we're watching
- Regulatory Momentum
- Whether the EU approval process for TRYNGOLZA accelerates following positive ESC data.
- Pipeline Progression
- The pace at which ION775 advances through Phase 2 trials and its potential to reduce dosing frequency.
- Competitive Positioning
- How Ionis leverages this data to solidify its leadership in sHTG against emerging therapies.
Related topics